VEGFA and age-related macular degeneration: Since 2004 when anti-vascular endothelial growth factor (anti-VEGF) was introduced to treat eye diseases, anti-VEGF has become the mainstay of treatment for many retinal diseases including neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edoema (DME) and macular edoema due to retinal vein occlusion (RVO) [1–7].